Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Evaluation of the Cepheid Xpert MTB/RIF assay
-
Published Date:
Nov 06 2014
-
Source:Expert Rev Mol Diagn. 15(1):9-22.
-
Language:English
-
[PDF-811.60 KB]
Details:
-
Alternative Title:Expert Rev Mol Diagn
-
Personal Author:
-
Description:The lack of capacity to provide laboratory confirmation of a diagnosis of tuberculosis disease (TB) is contributing to enormous gaps in the ability to find, treat and follow TB patients. WHO estimates that globally only about 57% of the notified new cases of pulmonary TB in 2012 and about 19% of rifampicin-resistant TB cases were laboratory confirmed. The Cepheid Xpert(®) MTB/RIF assay has been credited with revolutionizing laboratory testing to aid in the diagnosis of TB and rifampicin-resistant TB. This semi-automated test can detect both the causative agent of TB and mutations that confer rifampicin resistance from clinical specimens within 2 h after starting the test. In this article, we review the performance of the test, its pathway to regulatory approval and endorsement, guidelines for its use and lessons learned from the implementation of the test in low-burden, high-resource countries and in high-burden, low-resource countries.
-
Subject:
-
Pubmed ID:25373876
-
Pubmed Central ID:PMC5875728
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
text/xml 
image/gif 
image/jpeg 
image/gif 
image/jpeg
No Related Documents.
Email
CDC-INFO
